This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).
Arena Pharma (ARNA) Down After Underwritten Public Offering
by Zacks Equity Research
Arena Pharmaceuticals, Inc.'s (ARNA) shares dropped more than 13% on Apr 18, after the company announced that it will be raising funds through an underwritten public offering.
Bristol-Myers and Nordic Ink Biomarker Collaboration Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.
Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug
by Zacks Equity Research
Rigel Pharmaceuticals, Inc. (RIGL) recently announced that it has filed a new drug application (NDA) to the FDA, for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment immune thrombocytopenia (ITP).
Roche's Hemophilia A Drug Positive in Second Phase III Study
by Zacks Equity Research
Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.
Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.
by Zacks Equity Research
Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.
Biogen to License Alzheimer Candidate from Bristol-Myers
by Zacks Equity Research
Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
by Zacks Equity Research
Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).
Roche Launches Antibody Test to Diagnose Prostate Cancer
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.
Pacira Focuses on Lead Candidate Exparel's Label Expansion
by Zacks Equity Research
We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.
Ohr Pharmaceutical Provides Update on Squalamine Study
by Zacks Equity Research
Ohr Pharmaceutical, Inc. (OHRP), announced it plans to amend the ongoing MAKO Study evaluating Squalamine (also known as OHR-102) in wet form of age-related macular degeneration (wet-AMD).
Ultragenyx's (RARE) XLH Drug Positive in Phase II Study
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23).
Valeant (VRX) Faces Pricing Issues, Generic Threats Loom
by Zacks Equity Research
Shares of Valeant Pharmaceuticals International, Inc. (VRX) hit a 52-week low of $10.08 on Apr 4.
Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy
by Zacks Equity Research
Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy
Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.
What Bargain Hunting? Tap 5 Stocks with Rising P/E Instead
by Zacks Equity Research
These five stocks with rising P/E may cross the barrier of value investing and can offer investors stellar gains.
Bayer Announced Positive Data for Cancer Drug Copanlisib
by Zacks Equity Research
Bayer Aktiengesellschaft (BAYRY) announced positive data on its experimental candidate copanlisib.
GlaxoSmithKline Initiates Phase III Study with Mepolizumab
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced the initiation of a phase III study with Nucala (mepolizumab,) in patients with severe hypereosinophilic syndrome (HES).
Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) recently announced that it has initiated a phase II trial to evaluate its pipeline candidate, poziotinib for the treatment of non-small cell lung cancer patients.
Roche's Rituxan Gets FDA Advisory Committee's Recommendation
by Zacks Equity Research
Roche Holding AG's (RHHBY) member, Genentech announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients with certain blood cancers.
Acorda Presents Data for Parkinson's Candidate CVT-301
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease.
Amgen's Leukemia Drug Accepted for Priority Review by FDA
by Zacks Equity Research
Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.
Corcept (CORT) Strives to Commercialize Key Drug Korlym
by Zacks Equity Research
We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.
Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.
New Strong Buy Stocks for March 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday